Literature DB >> 4591151

Plasma levels of procaine amide after administration of conventional and sustained-release tablets.

E Karlsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4591151     DOI： 10.1007/bf00644740

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  Absorption of alprenolol in man from tablets with different rates of release.

Authors:  R Johansson; C G Regårdh; J Sjögren
Journal:  Acta Pharm Suec       Date:  1971-03

2.  Antiarrhythmic prophylaxis with procainamide in acute myocardial infarction.

Authors:  J Koch-Weser; S W Klein; L L Foo-Canto; J A Kastor; R W DeSanctis
Journal:  N Engl J Med       Date:  1969-12-04       Impact factor: 91.245

3.  Arrhythmia prophylaxis with procaine amide: plasma concentrations in relation to dose.

Authors:  P Collste; E Karlsson
Journal:  Acta Med Scand       Date:  1973-11

4.  Procainamide dosage schedules, plasma concentrations, and clinical effects.

Authors:  J Koch-Weser; S W Klein
Journal:  JAMA       Date:  1971-03-01       Impact factor: 56.272

5.  Metabolism of procainamide in rhesus monkey and man.

Authors:  J Dreyfuss; J T Bigger; A I Cohen; E C Schreiber
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875
  5 in total
  10 in total

1.  Elimination rate of N-acetylprocainamide after a single intravenous dose of procainamide hydrochloride in man.

Authors:  C Graffner
Journal:  J Pharmacokinet Biopharm       Date:  1975-04

2.  Acetylator phenotype and the clinical pharmacology of slow-release procainamide.

Authors:  W Campbell; W J Tilstone; D H Lawson; I Hutton; T D Lawrie
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

Review 3.  Is there an ideal antiarrhythmic drug? A review--with particular reference to class I antiarrhythmic agents.

Authors:  K A Muhiddin; P Turner
Journal:  Postgrad Med J       Date:  1985-08       Impact factor: 2.401

4.  Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels.

Authors:  E Karlsson
Journal:  Br Heart J       Date:  1975-07

5.  Procainamide absorption studies to test the feasibility of using a sustained-release preparation.

Authors:  T R Shaw; C R Kumana; C M Kaye; C Padgham; T Kaspi; J Hamer
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

6.  Acetylation of procaine amide in man. A preliminary communication.

Authors:  E Karlsson; G Aberg; P Collste; L Molin; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1975       Impact factor: 2.953

7.  Acetylation of procaine amide in man studied with a new gas chromatographic method.

Authors:  E Karlsson; L Molin; B Norlander; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1974-12       Impact factor: 4.335

8.  A pharmacokinetic comparison of two sustained-release oral procainamide preparations.

Authors:  P Hore; P Bones; T Rollinson; H Ikram
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of procainamide.

Authors:  E Karlsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

10.  Significance of the acetylation phenotype and the therapeutic effect of procainamide.

Authors:  P Schröder; N A Klitgaard; E Simonsen
Journal:  Eur J Clin Pharmacol       Date:  1979-02-19       Impact factor: 2.953
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.